HHS Announces First 10 Drugs Up for Price Negotiation
The US Department of Health and Human Services (HHS), through the Centers for Medicare& Medicaid Services, recently selected the 10 drugs for which they will begin negotiating prices as part of the Inflation Reduction Act. The medications are Eliquis; Enbrel; Entresto; Farxiga; Fiasp, Fiasp FlexTouch, Fiasp PenFill, NovoLog, NovoLog FlexPen, NovoLog PenFill; Imbruvica; Januvia; Jardiance; Stelara; and Xarelto. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - September 13, 2023 Category: General Medicine Source Type: research
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog ®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study
ConclusionsMYL-1601D demonstrated similar immunogenicity, efficacy, and safety profiles to Ref-InsAsp-US in patients with T1D over 24 weeks.Clinical Trial Registration ClinicalTrials.gov:NCT03760068. (Source: BioDrugs)
Source: BioDrugs - September 17, 2022 Category: Drugs & Pharmacology Source Type: research
How Hospitals Analyze and Learn from Adverse Events
In this session, the speaker walked through the steps institutions practicing a safety culture take to address medical errors. As a lead-in, Dr. Steinberg reminded us that two of the important parts of a culture of safety are a just culture and a reporting culture.
Dr. Bonsall
In a just culture, acceptable and unacceptable behaviors are clearly defined; individuals are accountable for their choices but not for problems with the system. In a reporting culture, people have trust and freely report hazardous conditions, near-misses, and errors. In an organization where people freely report hazardous conditions, safety mea...
Source: The Hospitalist - July 1, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: Business of Medicine Career Employees Hospital Medicine SHM Converge Source Type: research
Fiasp Confused with NovoLOG
No abstract available (Source: Home Healthcare Nurse)
Source: Home Healthcare Nurse - November 1, 2021 Category: Nursing Tags: ISMP MEDICATION SAFETY Source Type: research
Placebo controlled phase II clinical trial: Safety and efficacy of combining intranasal insulin & amp; acute exercise
This study provides preliminary evidence to suggest t hat exercise is not associated with an increase in risk when combined with lower doses of intranasal insulin.Clinical trial registration The trial is registered at ClinicalTrials.gov, number NCT04292535. (Source: Metabolic Brain Disease)
Source: Metabolic Brain Disease - April 15, 2021 Category: Neurology Source Type: research
Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
ConclusionsEfficacy and safety (including immunogenicity) profiles of SAR-Asp are similar to those of NN-Asp over 52 weeks in adults with diabetes irrespective of prior type of mealtime insulin.Trial RegistrationClinicalTrials.gov identifier: NCT03211858. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 11, 2021 Category: Endocrinology Source Type: research
Lyumjev - A New Insulin Lispro for Diabetes
Date: October 19, 2020
Issue #:
1609Summary:
The FDA has approved insulin lispro-aabc (Lyumjev–
Lilly), a faster-acting formulation of insulin lispro(Humalog), for treatment of type 1 and type 2 diabetes
in adults.Fiasp, a faster-acting formulation of insulin
aspart(Novolog), was approved in 2017. (Source: The Medical Letter)
Source: The Medical Letter - September 14, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial
Diabetes Technology&Therapeutics, Ahead of Print. (Source: Diabetes Technology and Therapeutics)
Source: Diabetes Technology and Therapeutics - January 27, 2020 Category: Endocrinology Authors: James Thrasher Sarit Polsky Lionel Hovsepian Irene Nowotny Suzanne Pierre B éatrice Bois De Fer Anuj Bhargava Bhaswati Mukherjee Satish K. Garg Source Type: research
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial
Diabetes Technology&Therapeutics, Ahead of Print. (Source: Diabetes Technology)
Source: Diabetes Technology - January 27, 2020 Category: Endocrinology Authors: James Thrasher Sarit Polsky Lionel Hovsepian Irene Nowotny Suzanne Pierre B éatrice Bois De Fer Anuj Bhargava Bhaswati Mukherjee Satish K. Garg Source Type: research
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial
Diabetes Technology&Therapeutics, Ahead of Print. (Source: Diabetes Technology and Therapeutics)
Source: Diabetes Technology and Therapeutics - January 27, 2020 Category: Endocrinology Authors: James Thrasher Sarit Polsky Lionel Hovsepian Irene Nowotny Suzanne Pierre B éatrice Bois De Fer Anuj Bhargava Bhaswati Mukherjee Satish K. Garg Source Type: research
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial
Diabetes Technology&Therapeutics, Ahead of Print. (Source: Diabetes Technology)
Source: Diabetes Technology - January 27, 2020 Category: Endocrinology Authors: James Thrasher Sarit Polsky Lionel Hovsepian Irene Nowotny Suzanne Pierre B éatrice Bois De Fer Anuj Bhargava Bhaswati Mukherjee Satish K. Garg Source Type: research
Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)
Date: May 6, 2019
Issue #:
1571Summary:
View the Expanded Table: Some Available Insulins (Source: The Medical Letter)
Source: The Medical Letter - April 26, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Admelog Afrezza Apidra Basaglar degludec Fiasp glargine Humalog Humulin insulin Lantus levemir Liraglutide lixisenatide Novolin Novolog Novorapid ReliOn Soliqua Toujeo Tresiba type 2 diabetes Xultophy Source Type: research
Insulins for Type 2 Diabetes
Date: May 6, 2019
Issue #:
1571Summary:
The goal of drug therapy for type 2 diabetes is to achieve
and maintain a near-normal glycated hemoglobin
(A1C) concentration without inducing hypoglycemia;
for most patients, the target A1C is<7%. Metformin
is the preferred first-line treatment, but most patients
with type 2 diabetes eventually require multidrug
therapy and/or insulin to achieve glycemic control. (Source: The Medical Letter)
Source: The Medical Letter - April 3, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Admelog Afrezza Apidra Basaglar degludec Detemir Fiasp glargine Humalog Humulin insulin Lantus levemir Liraglutide lixisenatide Novolin Novolog Novorapid ReliOn Soliqua Toujeo Tresiba type 2 diabetes Xultophy Source Type: research
Fiasp - Another Insulin Aspart Formulation for Diabetes
Date: January 1, 2018
Issue #:
1537Summary:
The FDA has approvedFiasp (Novo Nordisk), a new
formulation of insulin aspart, to improve glycemic
control in adults with diabetes.Fiasp is described by
the manufacturer as faster-acting than conventional
insulin aspart(Novolog). (Source: The Medical Letter)
Source: The Medical Letter - November 29, 2017 Category: Drugs & Pharmacology Authors: admin Source Type: research
